STCube

STCube EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of STCube (052020.KQ) as of Oct 24, 2026 is -56.00. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -44.07 — a change of 27.06% (lower).

EV/OCF

-56.00

YoY

27.06%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of STCube is 2025 -56.00 . EV/OCF (Enterprise Value to Operating Cash Flow) of STCube was 2024 -44.07 . It decreases by 27.06% lower compared to the previous year.

The STCube EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-180.52 KRW
Jan 1, 2019
-5,588.86 KRW
Jan 1, 2020
-108.09 KRW
Jan 1, 2021
-63.68 KRW
Jan 1, 2022
-65.71 KRW
Jan 1, 2023
-43.65 KRW
Jan 1, 2024
-44.07 KRW
Jan 1, 2025
-56.00 KRW
The STCube EV/OCF history
YEAREV/OCFYoY
-56.00+27.06%
-44.07+0.96%
-43.65-33.57%
-65.71+3.19%
-63.68-41.09%
-108.09-98.07%
-5,588.86+2,996.02%
-180.52+86.79%
-96.64-153.77%
179.75-168.45%
-262.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

EV/OCF (Enterprise Value to Operating Cash Flow) of STCube is -56.00 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of STCube changed from -44.07 to -56.00, representing a 27.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) STCube since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s STCube with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — STCube

All Key Metrics — STCube